Welcome to BioArctic’s website. In order to optimize your use of our website we use cookies. If you want more information about our cookie policy, please read more here. By continuing, you agree to our use of cookies.

Close

Svenska

Home
About us
About us
Research and development
Research and development
Governance
Governance
Investors
Investors
Media
Media
- Press releases
  
  News
- Image bank
- Subscribe
- Contacts
Career
Contacts
Contacts
- Office
- Investors
- Media

Svenska

Search for:

AD1502 – Alzheimer’s disease

AD1502 is an innovative project to develop a disease modifying treatment for prodromal and mild Alzheimer’s disease.

bioarctic-alzheimers-disease-module-001

Alzheimer’s disease

Halting the disease progression would lead to great benefits to patients, families and caregivers.

Research and development

Proud partner of:

About us

About BioArctic
CEO Gunilla Osswald presents BioArctic
Vision and mission
Culture and values
Objective and strategy
Collaborations and partners
Sustainability
Organization
History

Research and development

Technology
Pipeline
Therapeutic Areas

Governance

Governance structure
Corporate Governance Reports
General Meeting
Nomination Committee
Board of Directors
Senior management
Remuneration
Internal audit and control
Audit
Articles of Association

Investors

The share
Financial reports
Prospectus
Presentations
Press releases
News
Calendar
Privacy policy – Shareholders
Subscribe
Contact

Media

Press releases
News
Image bank
Subscribe
Contacts

Career

Career

Contacts

Office
Investors
Media

BioArctic AB, Warfvinges väg 35, SE-112 51 Stockholm, Sweden. Phone: +46 8 695 69 30. E-mail: info@bioarctic.se. Registration number: 556601-2679.

© 2019 BioArctic AB – All rights reserved

About Cookies
Processing of personal data